This randomized phase III study demonstrated that the long-term efficacy of CT-P10 after two courses was comparable to that of reference rituximab from the USA and the EU in patients with rheumatoid arthritis.

Pharmacokinetic, pharmacodynamic, immunogenicity, and safety findings were also comparable between groups up to week 48.

These data provide evidence for the long-term use of CT-P10 in terms of its efficacy and safety in clinical practice, supporting the recent approval of CT-P10 for the treatment of patients with rheumatoid arthritis.